- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J.,...
“ On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 “ “ Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation “ “ Oral Plogosertib Preclinical Data Support...
#NAME?
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host...